Youngjae You, Ph.D.

Professor

Department of Pharmaceutical Sciences

Phone (405) 271-6593 x47473

Fax (405) 271-7505

Office CPB 317

Email youngjae-you@ouhsc.edu


Summary

Photodynamic therapy (PDT) is an emerging tool for treating cancers that is selective and causes minimum side effects compared to current standard treatment options such as surgery, radiotherapy, and chemotherapy. In PDT, the damage on tumor occurs from the combination of a small molecule (photosensitizer, PS), oxygen, and the light of near IR range (650-800 nm). We are interested in developing new PSs which overcome problems of current photosensitizers. The first goal is to develop new photosensitizers absorbing long-wave length (>750 nm) with high extinction coefficient. The second goal is to achieve higher selectivity toward cancer cells/tumor tissue over surrounding normal cells/tissues. To this end, unique characteristics of cancer cells/tumor tissue are taken advantage for our goal. Currently, mitochondria-targeted photosensitizers are under development. Side effects of chemotherapeutic drugs are not just additional burdens to cancer patients but real problems during the treatments. Selectivity toward cancer cells of drugs is an important issue. Various drug delivery strategies employing nano-technologies (liposomes, polymers, quantum dots, dendrimers, and etc.) have been developed and innovative targeting methods are established for passive and active targeting. Another key factor for successful site-specific drug delivery is how to control the release of drug from such delivery vehicles. Current strategies using enzyme, pH, or chemicals are either physiological condition dependents or not biocompatible. We are developing a new strategy for controlling drug-release with light.



Research

Photodynamic therapy (PDT) is an emerging tool for treating cancers that is selective and causes minimum side effects compared to current standard treatment options such as surgery, radiotherapy, and chemotherapy. In PDT, the damage on tumor occurs from the combination of a small molecule (photosensitizer, PS), oxygen, and the light of near IR range (650-800 nm). We are interested in developing new PSs which overcome problems of current photosensitizers. The first goal is to develop new photosensitizers absorbing long-weave length (>750 nm) with high extinction coefficient. The second goal is to achieve higher selectivity toward cancer cells/tumor tissue over surrounding normal cells/tissues. To this end, unique characteristics of cancer cells/tumor tissue are taken advantage for our goal. Currently, mitochondria-targeted photosensitizers are under development. Side effects of chemotherapeutic drugs are not just additional burdens to cancer patients but real problems during the treatments. Selectivity toward cancer cells of drugs is an important issue. Various drug delivery strategies employing nano-technologies (liposomes, polymers, quantum dots, dendrimers, and etc.) have been developed and innovative targeting methods are established for passive and active targeting. Another key factor for successful site-specific drug delivery is how to control the release of drug from such delivery vehicles. Current strategies using enzyme, pH, or chemicals are either physiological condition dependents or not biocompatible. We are developing a new strategy for controlling drug-release with light.



Research Interests

www.medichematok.com/home





Education & Experience

Ph.D. in Medicinal Chemistry

Chungnam National University, Taejon, Korea

2001

M.S. in Medicinal Chemistry

Chungnam National University, Taejon, Korea

1997

B.S. in Pharmacy

Chungnam National Univedrsity, Taejon, Korea

1994


Honors & Awards

Professional Awards

IDeA Award, Breast Cancer Research Program

CDMRP, DoD

Research/Scholarship Support Award

SDSU




Publications & Presentations


. . Presented at 12/12/2018;



Publications & Presentations

1 2 3 4 > >>
  • Li M, Thapa P, Rajaputra P, Bio M, Peer C J, Figg W D, You Y, Woo S. Quantitative modeling of the dynamics and intracellular trafficking of far-red light-activatable prodrugs: implications in stimuli-responsive drug delivery system. Journal of pharmacokinetics and pharmacodynamics. 2017; 44 : 521-536
  • Thapa P, Li M, Karki R, Bio M, Rajaputra P, Nkepang G, Woo S, You Y. Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells. ACS OMEGA. 2017; 2 : 6349-6360
  • Li M, Rajaputra P, Bio M, Peer C J, Figg W D, You Y, Woo S. Quantitative Modeling of the Dynamics and Intracellular Trafficking of Far-Red Light-Activatable Prodrugs: Implications in Stimuli-Responsive Drug Delivery System. Journal of Pharmacokinetics and Pharmacodynamics. 2017; 44 : 521-536
  • Bio M, Rajaputra P, Lim I, Thapa P, Tienabeso B, Hurst R E, You Y. Efficient activation of a visible light-activatable CA4 prodrug through intermolecular photo-unclick chemistry in mitochondria. Chemical communications (Cambridge, England). 2017; 53 : 1884-1887
  • Bio M, Rajaputra P, Lim I, Thapa P, Tienabeso B, Hurst R E, You Y. Efficient activation of a visible light-activatable CA4 prodrug through intermolecular photo-unclick chemistry in mitochondria. Chemical Communications. 2017; 53 : 1884-1887
  • 1 2 3 4 > >>